Related Experiment Video
Updated: Jul 11, 2025

Expression and Purification of Virus-like Particles for Vaccination
Published on: June 2, 2016
Bacteriophage Virus-Like Particles: Platforms for Vaccine Design
1School of Veterinary Medicine, Texas Tech University, Amarillo, TX, USA. etumban@ttu.edu.
Abstract:
Virus-like particles (VLPs) derived from bacteriophages have many applications in biomedical sciences, especially in the development of candidate vaccines against viral and bacterial infections. Bacteriophage VLPs can be manufactured cheaply and in large quantities in bacteria compared to eukaryotic expression systems. In addition to this, bacteriophage VLPs are excellent platforms for vaccine design for the following reason: Humans do not have preexisting antibodies against bacteriophage VLPs. Thus, antigens displayed on bacteriophage VLP platforms are expected to be highly immunogenic. As such, VLPs derived from MS2, PP7, Qβ, AP205, P22 bacteriophages, etc. have been used to develop candidate vaccines against human infectious and noninfectious agents. This mini-review summarizes data from some of the candidate bacteriophage-based VLP peptide vaccines that have been developed. The review also highlights some strategies used to develop the candidate bacteriophage-based VLP peptide vaccines.
More Related Videos
08:07A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
Published on: July 25, 2022
05:15Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
Published on: February 10, 2022
Related Concept Videos
DNA Bacteriophages
Lytic Cycle of Bacteriophages
Viral Structure
Lysogenic Cycle of Bacteriophages
Viral Replication: Lytic Cycle
Viral Replication: Lysogenic Cycle